Aldesleukin Completed Phase 2 Trials for Chronic Myeloproliferative Disorders / Renal Cancers / Neuroblastomas / Myelodysplastic Syndromes / Testicular germ cell tumour / Ovarian Cancer / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Gestational Trophoblastic Disease / Sarcomas / Breast Cancer / Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00003408Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
NCT00616720Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
NCT00274846Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00003148Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
NCT00005948Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia
NCT00008190Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
NCT00059904Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
NCT00006264Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma
NCT00004231Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
NCT00853021Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
NCT00085436DC Vaccine Combined With IL-2 and IFN╬▒-2a in Treating Patients With mRCC
NCT00031564Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
NCT00100906Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer